{"id":"dose-matched-placebo-to-suvorexant","safety":{"commonSideEffects":[{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Suvorexant works by blocking orexin receptors (OX1R and OX2R) in the brain, which suppresses wakefulness-promoting signals and facilitates sleep onset and maintenance. The dose-matched placebo is an inert formulation designed to match the active drug in appearance and administration for blinded clinical trial comparison.","oneSentence":"This is a placebo control formulation matched to suvorexant, an orexin receptor antagonist used to promote sleep.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:52.093Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Insomnia (sleep onset and/or sleep maintenance) — placebo control in phase 3 trials"}]},"trialDetails":[{"nctId":"NCT05546554","phase":"PHASE2","title":"Trial of Suvorexant for Sleep in Children With Autism","status":"RECRUITING","sponsor":"Stanford University","startDate":"2023-08-09","conditions":"Autism, Autism Spectrum Disorder","enrollment":26},{"nctId":"NCT06162663","phase":"PHASE4","title":"Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors","status":"TERMINATED","sponsor":"Medical University of South Carolina","startDate":"2024-09-20","conditions":"Breast Cancer, Insomnia","enrollment":5},{"nctId":"NCT04571944","phase":"PHASE3","title":"Efficacy and Safety of Suvorexant (MK-4305) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium (MK-4305-085)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-10-22","conditions":"Delirium","enrollment":207},{"nctId":"NCT02750306","phase":"PHASE3","title":"Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-23","conditions":"Sleep Initiation and Maintenance Disorders, Alzheimer Disease","enrollment":285},{"nctId":"NCT03657355","phase":"PHASE1","title":"Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2018-09-07","conditions":"Healthy Recreational Drug Users","enrollment":63},{"nctId":"NCT01097629","phase":"PHASE3","title":"Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-03","conditions":"Primary Insomnia","enrollment":1020},{"nctId":"NCT00792298","phase":"PHASE2","title":"Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-11-05","conditions":"Primary Insomnia","enrollment":254},{"nctId":"NCT01021813","phase":"PHASE3","title":"A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-12-10","conditions":"Insomnia","enrollment":781},{"nctId":"NCT01097616","phase":"PHASE3","title":"Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-05","conditions":"Primary Insomnia","enrollment":1023},{"nctId":"NCT01293006","phase":"PHASE1","title":"Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03-25","conditions":"Insomnia","enrollment":25},{"nctId":"NCT01311882","phase":"PHASE1","title":"A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04","conditions":"Insomnia","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Dose-matched Placebo to Suvorexant","genericName":"Dose-matched Placebo to Suvorexant","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control formulation matched to suvorexant, an orexin receptor antagonist used to promote sleep. Used for Insomnia (sleep onset and/or sleep maintenance) — placebo control in phase 3 trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}